Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

被引：72

作者：

Green, Alexa S. ^{[1
,2
,3
,4
]}

Maciel, Thiago T. ^{[5
,6
,7
,8
]}

Hospital, Marie-Anne ^{[1
,2
,3
]}

Yin, Chae ^{[9
]}

Mazed, Fetta ^{[1
,2
,3
]}

Townsend, Elizabeth C. ^{[10
]}

Pilorge, Sylvain ^{[1
,2
,3
,11
]}

Lambert, Mireille ^{[1
,2
,3
]}

Paubelle, Etienne ^{[5
,6
,7
,8
]}

Jacquel, Arnaud ^{[11
]}

Zylbersztejn, Florence ^{[5
,6
,7
,8
]}

Decroocq, Justine ^{[5
,6
,7
,8
]}

Poulain, Laury ^{[1
,2
,3
]}

Sujobert, Pierre ^{[1
,2
,3
]}

Jacque, Nathalie ^{[1
,2
,3
]}

Adam, Kevin ^{[1
,2
,3
]}

So, Jason C. C. ^{[9
]}

Kosmider, Olivier ^{[1
,2
,3
]}

Auberger, Patrick ^{[11
]}

Hermine, Olivier ^{[5
,6
,7
,8
]}

Weinstock, David M. ^{[10
]}

Lacombe, Catherine ^{[1
,2
,3
]}

Mayeux, Patrick ^{[1
,2
,3
]}

Vanasse, Gary J. ^{[12
]}

Leung, Anskar Y. ^{[9
]}

Moura, Ivan C. ^{[5
,6
,7
,8
]}

Bouscary, Didier ^{[1
,2
,3
]}

Tamburini, Jerome ^{[1
,2
,3
]}

机构：

[1] CNRS, Inst Cochin, INSERM U1016, Dept Dev Reprod Canc,UMR 8104, F-75014 Paris, France

[2] Univ Paris 05, Fac Med, Sorbonne Paris Cite, F-75005 Paris, France

[3] Ligue Natl Canc LNCC, Equipe Labellisee, F-75013 Paris, France

[4] Charles Nicolle Univ Hosp, Dept Hematol, F-76000 Rouen, France

[5] INSERM UMR 1163, Lab Cellular & Mol Mech Hematol Disorders & Thera, F-75015 Paris, France

[6] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, F-75015 Paris, France

[7] CNRS, ERL 8254, F-75015 Paris, France

[8] Lab Excellence GR Ex, F-75015 Paris, France

[9] Univ Hong Kong, Li Ka Shing LKS Fac Med, Dept Med, Div Hematol, Hong Kong, Hong Kong, Peoples R China

[10] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[11] INSERM U1065, C3M Team 2, Cell Death Differentiat Inflammat & Canc, F-06204 Nice, France

[12] Novartis Inst BioMed Res, Cambridge, MA 02139 USA

来源：

SCIENCE ADVANCES | 2015年 / 1卷 / 08期

关键词：

D O I：

10.1126/sciadv.1500221

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide shortterm disease control, but relapse invariably occurs within months. Pim protein kinases are oncogenic FLT3-ITD targets expressed in AML cells. We show that increased Pim kinase expression is found in relapse samples from AML patients treated with FLT3 inhibitors. Ectopic Pim-2 expression induces resistance to FLT3 inhibition in both FLT3ITD- induced myeloproliferative neoplasm and AML models in mice. Strikingly, we found that Pim kinases govern FLT3-ITD signaling and that their pharmacological or genetic inhibition restores cell sensitivity to FLT3 inhibitors. Finally, dual inhibition of FLT3 and Pimkinases eradicates FLT3-ITD+ cells including primary AML cells. Concomitant Pim and FLT3 inhibition represents a promising new avenue for AML therapy.

引用

页数：13

共 50 条

[31] MicroRNA networks in FLT3-ITD acute myeloid leukemia
Hoang, Dinh Hoa
Zhao, Dandan
Branciamore, Sergio
Maestrini, Davide
Rodriguez, Ivan R.
Kuo, Ya-Huei
Rockne, Russell
Khaled, Samer K.
Zhang, Bin
Nguyen, Le Xuan Truong
Marcucci, Guido
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (16)
[32] FLT3 inhibitors in acute myeloid leukemia
不详
ANNALS OF HEMATOLOGY, 2008, 87 : S87 - S89
[33] FLT3 Inhibitors for Acute Myeloid Leukemia
Lancet, Jeffrey E.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 573 - 575
[34] FLT3 inhibitors in acute myeloid leukemia
el-Shami, Khaled
Stone, Richard M.
Smith, B. Douglas
EXPERT REVIEW OF HEMATOLOGY, 2008, 1 (02) : 153 - 160
[35] FLT3 inhibitors in acute myeloid leukemia
Pastore, Domenico
DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2016, 4 (01): : 14 - 21
[36] The FLT3 tyrosine kinase receptor ITD mutation controls its expression and drug resistance in acute myeloid leukemia
Alqahtani, Taha
MacEwan, David
CANCER RESEARCH, 2024, 84 (06)
[37] An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor
Kim, Ryan S.
Yaghy, Antonio
Wilde, Lindsay R.
Shields, Carol L.
JAMA OPHTHALMOLOGY, 2020, 138 (04) : 418 - 419
[38] High FLT3 mRNA expression without FLT3-ITD in infants with acute myeloid leukernia
Shimada, Akira
Yamada, Miho
Yamashita, Yuka
Yokozawa, Toshiya
Tomizawa, Daisuke
Kinoshita, Akitoshi
Taga, Takashi
Tawa, Akio
Taki, Tomohiko
Hayashi, Yasuhide
Fujimoto, Junichiro
Horibe, Keizo
Adachi, Souichi
CANCER RESEARCH, 2012, 72
[39] Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia
Levis, Mark
FUTURE ONCOLOGY, 2014, 10 (09) : 1571 - 1579
[40] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
Melgar, Katelyn
Walker, MacKenzie
Jiang, Jian-kang
Wilson, Kelli
Mulloy, James C.
Thomas, Craig J.
Starczynowski, Daniel T.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →